AI‑driven discovery activity accelerated with two notable developments. Insilico Medicine signed an $888 million collaboration with Servier to discover oncology candidates using its AI platforms. Separately, 1910 published PEGASUS, an AI model that designs cell‑permeable macrocyclic peptides and promises to expand access to intracellular targets. Together, the announcements highlight both commercial partnerings and technical advances in AI‑enabled modalities from small molecules to macrocyclic peptides.